Kuros Biosciences Ltd. (CSBTF)
24.00
0.00 (0.00%)
USD |
OTCM |
Oct 09, 16:00
Kuros Biosciences Max Drawdown (5Y) : 74.53% for Sept. 30, 2026
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| September 30, 2026 | 74.53% |
| August 31, 2026 | 74.53% |
| July 31, 2026 | 74.53% |
| June 30, 2026 | 74.53% |
| May 31, 2026 | 92.65% |
| April 30, 2026 | 93.13% |
| March 31, 2026 | 93.13% |
| February 28, 2026 | 93.29% |
| January 31, 2026 | 93.73% |
| December 31, 2025 | 93.73% |
| November 30, 2025 | 93.76% |
| October 31, 2025 | 93.76% |
| September 30, 2025 | 94.49% |
| August 31, 2025 | 94.49% |
| July 31, 2025 | 94.49% |
| June 30, 2025 | 94.49% |
| May 31, 2025 | 96.53% |
| April 30, 2025 | 96.53% |
| March 31, 2025 | 96.53% |
| February 28, 2025 | 96.53% |
| January 31, 2025 | 96.53% |
| December 31, 2024 | 98.79% |
| November 30, 2024 | 98.79% |
| October 31, 2024 | 98.79% |
| September 30, 2024 | 98.79% |
| Date | Value |
|---|---|
| August 31, 2024 | 98.79% |
| July 31, 2024 | 98.79% |
| June 30, 2024 | 98.79% |
| May 31, 2024 | 98.79% |
| April 30, 2024 | 98.79% |
| March 31, 2024 | 99.21% |
| February 29, 2024 | 99.27% |
| January 31, 2024 | 99.48% |
| December 31, 2023 | 99.48% |
| November 30, 2023 | 99.48% |
| October 31, 2023 | 99.48% |
| September 30, 2023 | 99.48% |
| August 31, 2023 | 99.48% |
| July 31, 2023 | 99.48% |
| June 30, 2023 | 99.48% |
| May 31, 2023 | 99.48% |
| April 30, 2023 | 99.48% |
| March 31, 2023 | 99.48% |
| February 28, 2023 | 99.48% |
| January 31, 2023 | 99.48% |
| December 31, 2022 | 99.48% |
| November 30, 2022 | 99.48% |
| October 31, 2022 | 99.48% |
| September 30, 2022 | 99.48% |
| August 31, 2022 | 99.48% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Max Drawdown (5Y) Benchmarks
| Molecular Partners AG | 89.59% |
| Basilea Pharmaceutica AG | 55.70% |
| Santhera Pharmaceuticals Holding AG | 98.31% |
| BeOne Medicines Ltd. | 69.96% |
| AC Immune SA | 89.55% |